Korea’s First Homegrown GLP-1 Cut Weight 9.75% at 40 Weeks, So Hanmi Will Fight Wegovy and Mounjaro on Price and Supply
Hanmi’s GLP-1 trails Wegovy and Mounjaro on weight loss, so its case rests on a low starting price and Korean supply.
CI read
Merck and Daiichi Pulled an ADC Filing as GSK Paid $110 Million for a KRAS Payload
Crowded topoisomerase I ADCs face a higher bar, while money moves to RAS payloads, bispecific ADCs and discovery tools.
Merck Has 26 Months to Move Keytruda Patients to a Shot Protected Until 2043
Merck’s Keytruda defence turns on one number: how many US patients are on the one-minute shot when biosimilars ship.
Jaypirca’s 80% Win Over Chemo Opens a First-Line CLL Fight With Three BTK Rivals
Jaypirca reaches first-line CLL on a win over chemo, and now has to take share from three covalent BTK inhibitors.
Retatrutide Cuts Weight 20.8% in Type 2 Diabetes, and Lilly Plans to File It as a Biologic
The efficacy is the headline. The filing route and a sensory side effect are the details that will shape the label.
FDA’s Surgical Robot Guidance Prefers Robotic Comparator Data, Which Mostly Means Measuring Challengers Against Intuitive
One test for every surgical robot, and by preferring robotic comparators it decides whose results set the score.
Qatar Became Foundayo’s Sixth Market as Lilly Claimed an Edge Over Oral Semaglutide 25 mg
Approvals market by market, and data built to shape the comparison with a Novo dose that has not launched.
China Cleared Jaypirca in Frontline CLL on a Win Over Chemotherapy and Non-Inferiority to Ibrutinib
The label reaches frontline CLL, but against a modern BTK inhibitor the evidence so far is a response rate.
Merck’s $4 Billion Daiichi ADC Pact Takes Its Third FDA Setback in Three Years
The $4bn deal’s first return keeps slipping toward 2028, the year Keytruda begins to lose protection.
Kodiak’s Zenkuda Put 54% of Wet AMD Patients on Six-Month Dosing, Four Years After an Extended-Dosing Miss
The molecule that failed on long intervals in 2022 now holds vision with most patients on six-month dosing.